Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
- PMID: 25065853
- DOI: 10.1016/j.ccr.2014.05.019
Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells
Abstract
Pathway-_targeted cancer drugs can produce dramatic responses that are invariably limited by the emergence of drug-resistant cells. We found that many drug-treated "oncogene-addicted" cancer cells engage a positive feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall drug response. This was observed in cancer cells driven by diverse activated kinases, including EGFR, HER2, ALK, and MET, as well as mutant KRAS. Specifically, MEK inhibition led to autocrine activation of Stat3 via the FGF receptor and JAK kinases, and pharmacological inhibition of MEK together with JAK and FGFR enhanced tumor regression. These findings suggest that inhibition of a Stat3 feedback loop may augment the response to a broad spectrum of drugs that _target pathways of oncogene addiction.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.Biol Pharm Bull. 2017 Aug 1;40(8):1306-1313. doi: 10.1248/bpb.b17-00271. Epub 2017 May 18. Biol Pharm Bull. 2017. PMID: 28515374
-
An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.Nat Cell Biol. 2014 May;16(5):457-68. doi: 10.1038/ncb2953. Epub 2014 Apr 20. Nat Cell Biol. 2014. PMID: 24747441 Free PMC article.
-
_targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.J Clin Invest. 2012 Jul;122(7):2637-51. doi: 10.1172/JCI62058. Epub 2012 Jun 1. J Clin Invest. 2012. PMID: 22653055 Free PMC article.
-
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.Oncogene. 2009 Aug;28 Suppl 1(Suppl 1):S24-31. doi: 10.1038/onc.2009.198. Oncogene. 2009. PMID: 19680293 Free PMC article. Review.
-
Management and future directions in non-small cell lung cancer with known activating mutations.Am Soc Clin Oncol Educ Book. 2014:e353-65. doi: 10.14694/EdBook_AM.2014.34.e353. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857124 Review.
Cited by
-
NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer.Cell Rep. 2015 Apr 7;11(1):98-110. doi: 10.1016/j.celrep.2015.03.012. Epub 2015 Apr 2. Cell Rep. 2015. PMID: 25843712 Free PMC article.
-
Carcinoembryonic Antigen Cell Adhesion Molecule 1 long isoform modulates malignancy of poorly differentiated colon cancer cells.Gut. 2016 May;65(5):821-9. doi: 10.1136/gutjnl-2014-308781. Epub 2015 Feb 9. Gut. 2016. PMID: 25666195 Free PMC article.
-
Functional screening implicates miR-371-3p and peroxiredoxin 6 in reversible tolerance to cancer drugs.Nat Commun. 2016 Aug 3;7:12351. doi: 10.1038/ncomms12351. Nat Commun. 2016. PMID: 27484502 Free PMC article.
-
Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes.Int J Cancer. 2015 Nov 15;137(10):2296-309. doi: 10.1002/ijc.29606. Epub 2015 Jun 5. Int J Cancer. 2015. PMID: 25991553 Free PMC article.
-
Stochastic modeling suggests that noise reduces differentiation efficiency by inducing a heterogeneous drug response in glioma differentiation therapy.BMC Syst Biol. 2016 Aug 11;10(1):73. doi: 10.1186/s12918-016-0316-x. BMC Syst Biol. 2016. PMID: 27515956 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous
